<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01922102</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002F2302</org_study_id>
    <nct_id>NCT01922102</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia</brief_title>
  <acronym>Brilliance</acronym>
  <official_title>A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of two different dosing regimens
      of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in
      patients with visual impairment due to choroidal neovascularization secondary to pathologic
      myopia (PM)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III, multi-center, randomized, double-masked, active-controlled study
      comparing 0.5 mg ranibizumab vs. vPDT therapy. The study includes 15 scheduled visits over 12
      months, and there will be two additional visits (2a, 3a) for subset of patients in whom PK
      analysis will be performed.

      There will be 3 periods in this study: Screening period-from Day -14 to Baseline; Treatment
      period-from Baseline to Month 11; Follow-up period-from Month 11 to Month 12 Patients will
      enter the 11 months Treatment period at Visit 2 (Day 1) if eligibility criteria are met and
      will be randomized in three treatment groups Group I ranibizumab 0.5 mg driven by VA
      stability criteria or Group II ranibizumab 0.5 mg driven by disease activity criteria or
      Group III vPDT (randomization ratio of 2:2:1) and will receive first treatment of either a
      ranibizumab injection and sham vPDT or sham injection and active vPDT and will return to the
      clinical center within 7 days to undergo safety assessments as well as assessments of the
      effect of treatment by the evaluating investigator. The following visits will be performed at
      one month intervals starting at Visit 4 and continuing through Visit 14.At all monthly visits
      (at/from Month 2 for group I, at/from Month 1 for group II and at/from Month 3 for group III)
      the decision for treatment will be made by the evaluating investigator based on the VA
      stability criteria and on the disease activity criteria. At Month 3 (visit 6) and at all
      following monthly visits for all three groups one of the three options can recommended by
      evaluating investigator: a) ranibizumab 0.5 mg, b) ranibizumab 0.5 mg + vPDT; c) vPDT. The
      treating investigator will then perform treatment based on randomization and masking
      requirements.

      At each monthly visit, patients will have a safety evaluation by the evaluating investigator
      prior to study treatment, consisting of visual acuity measurements, ophthalmic examinations
      and evaluation of adverse events and vital signs. Routine hematology, chemistry, and
      urinalysis profiles will be obtained at Visit 6, 9 and 12 (Month 3, 6 and 9). At Month 12
      several procedures and assessments will be performed which are required at study completion
      visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2013</start_date>
  <completion_date type="Actual">September 14, 2016</completion_date>
  <primary_completion_date type="Actual">September 14, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline BCVA to the average level of BCVA (letters) over all monthly post-baseline assessments: BCVA change; by measuring BCVA score at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts</measure>
    <time_frame>Month 1 to Month 3</time_frame>
    <description>Superior efficacy of 0.5 mg ranibizumab administered based on visual acuity stability criteria and/or disease activity re-treatment criteria compared to vPDT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>average level of BCVA (letters); BCVA change; by measuring BCVA score at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts</measure>
    <time_frame>Month 1 to Month 6</time_frame>
    <description>demonstrate non-inferiority of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria as assessed by the change from baseline BCVA to the average level of BCVA over all monthly assessments from Month 1 to Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average level of BCVA (letters); BCVA change; by measuring BCVA score at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the efficacy of the ranibizumab treatment groups as assessed by the change from baseline BCVA to the average level of BCVA over all monthly assessments from Month 1 to Month 12 and based on the time course of BCVA changes from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in BCVA; BCVA score measured at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts</measure>
    <time_frame>12 Months</time_frame>
    <description>To compare BCVA improvement ≥10 and ≥15 letters or BCVA reaching 84 letters, and BCVA loss ≥10 and ≥15 letters for each month between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in retinal thickness measured on OCT image by Reading center</measure>
    <time_frame>12 Months</time_frame>
    <description>To evaluate the time course of CRT/CSFT changes from baseline in the treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNV leakage presence measured on Fluorescein angiography image by Reading center</measure>
    <time_frame>12 Months</time_frame>
    <description>To compare presence of active leakage over time up to Month 12 in the treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 Months</time_frame>
    <description>To assess the impact on patient functioning and quality of life supported by ranibizumab 0.5 versus vPDT as assessed by the NEI-VFQ-25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injections and period (time) between injections</measure>
    <time_frame>12 months</time_frame>
    <description>To assess treatment pattern with ranibizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and incidence of the AEs</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the safety and tolerability of 0.5 mg ranibizumab and vPDT</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">456</enrollment>
  <condition>Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg ranibizumab driven by visual acuity stability criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg ranibizumab driven by disease activity criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>verteporfin PDT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5mg</intervention_name>
    <description>0.5 mg ranibizumab (intravitreal injections)</description>
    <arm_group_label>Group I</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rranibizumab 0.5 mg</intervention_name>
    <description>0.5 mg ranibizumab (intravitreal injections)</description>
    <arm_group_label>Group II</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verteporfin PDT</intervention_name>
    <description>Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application</description>
    <arm_group_label>Group III</arm_group_label>
    <other_name>Visudyne</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Visual impairment due to CNV secondary to PM.

          -  Best corrected visual acuity in the study eye &gt; 24 and &lt; 78 ETDRS letters.

          -  High myopia (&gt; -6D),

          -  anterio-posterior elongation &gt; 26 mm; posterior changes compatible with the pathologic
             myopia.

          -  Either CNV locations in the study eye: subfoveal, juxtafoveal, extrafoveal.

        Exclusion Criteria:

          -  Some preexisting eye disorders or systemic diseases;-Blood pressure &gt; 150/90 mmHg

          -  Prior focal/grid laser to the macular area -History of treatment with any anti-VEGF or
             verteporfin PDT in the study eye

          -  Intravitreal treatment with corticosteroids or intraocular surgery within last 3
             months in the study eye

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430070</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wu Xi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300070</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100176</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hongkong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chandigarh</city>
        <state>Haryana</state>
        <zip>160 030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vanchiyoor</city>
        <state>Kerala</state>
        <zip>695035</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Orissa</state>
        <zip>751024</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641 014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Angamaly</city>
        <zip>683572</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110 029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pusan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <state>Metro Manila</state>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <state>Metro Manila</state>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Khon Kaen</city>
        <state>THA</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nakornphathom</city>
        <zip>73210</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pathologic myopia (PM), choroidal neovascularization (CNV), ranibizumab, verteporfin PDT, Brilliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>September 11, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>April 16, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

